在患有微观卫星不稳定性和BRCA2突变的mCRPC男性中,pembrolizumab后完全缓解
Casey Moore1, Isabel Naraine1, Tian Zhang1
1Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390-8852, United States.
The oncologist
|June 26, 2024
概括
转移性激素敏感前列腺癌 (mHSPC) 可以迅速进展. 早期的分子测试显示了微卫星的不稳定性,导致前列腺癌病例中对 pembrolizumab 的强烈反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌是男性的主要恶性瘤,在美国,每8例中就有1例被诊断为癌症.
- 转移性激素敏感前列腺癌 (mHSPC) 呈现异质性,影响治疗反应.
- 目前针对雄激素受体通路的治疗方法具有可变的疗效.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...